Throughout this proposal, we have emphasized the need to move research findings into the clinic. The new Shared Resource and Methodology dispussed below will provide important new areas of expertise needed by our investigators on both sides of the clinical interface. In order to link the developing shared resources with our Cancer Center members, we propose to use CCSG pilot project support specifically for projects that utilize the new shared resources. 7.5.2.1 TRANSLATIONAL METHODOLOGY PILOT FUNDING! In order to fully utilize the capabilities of the Translational Methodology, we will create a new mechanism for pilot support designed to move a project through from discovery to drug scale-up. Support for a single project funded at $100,000 per year for one year will help ensure that new cancer therapeutics are using this methodology. 7.5.2.2 CLINICAL PHARMACOLOGY PILOT SUPPORT New therapies may fail for many reasons. We are beginning to understand how pharmacokinetics affect benefit and toxicity of many new drugs. Many clinical studies frequently do not incorporate pharmacokinetic, pharmaCodynamic, or pharmacogenetic evaluation into their trial design because of cost. In this pilot mechanism, we will offer support for these types of studies in investigator-initiated clinical trials. The purpose of this mechanism of pilot support is not meant to fund the entire clinical trial Instead, this pilot funding will serve as a supplement to ongoing clinical trials. A total amount of $50,000 per year is committed to this program from CCSG funds. There will be no uniform date for application for this mechanism given the nature of clinical investigation. Instead, this mechanism will be promoted to the Cancer Center membership, and a review of each proposal will be initiated by the Clinical Research Leadership committee and Drs. Jacobson and Kirstein. If the study is deemed to be of sufficient merit, then it will be funded and funds will be expended on a first-come, first-served basis. Other meritorious trials can be supported by philanthropic funds if they are proposed after the CCSG support is committed. In addition to these specific mechanisms, the existing pilot project support will be maintained (TTURC, Women's Cancer, Brainstorm, Population Science, Sarcoma). The CCSG will support some of these mechanisms and may be supplemented with philanthropic support. 7.5.2.3 ONGOING SUPPORT OF EXISTING AWARD MECHANISMS We propose to continue to bur annual Brainstorm awards to promote interprogrammatic research, as well as specific awards in the areas of population sciences and translational research. Although the majority of these awards will be funded through philanthropic support, we have budgeted $200,000 in CCSG support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-15
Application #
8449972
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$223,486
Indirect Cost
$75,482
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Pierpont, Elizabeth I; Hudock, Rebekah L; Foy, Allison M et al. (2018) Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1. J Neurodev Disord 10:21
Carlson, Erik S; Upadhyaya, Pramod; Villalta, Peter W et al. (2018) Analysis and Identification of 2'-Deoxyadenosine-Derived Adducts in Lung and Liver DNA of F-344 Rats Treated with the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of its Metabolite 4-(Methylnitrosamino)-1-(3-p Chem Res Toxicol 31:358-370
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Hupp, Meghan; Williams, Sarah; Dunnette, Brian et al. (2018) Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. Hum Pathol :
Rashidi, Armin; Shanley, Ryan; Holtan, Shernan G et al. (2018) Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:2190-2196
Ma, Bin; Zarth, Adam T; Carlson, Erik S et al. (2018) Methyl DNA Phosphate Adduct Formation in Rats Treated Chronically with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 31:48-57
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891

Showing the most recent 10 out of 1013 publications